AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
(Full text of a statement. Contact details below.)
LEWISTON, N.Y., April 1 PRNewswire-FirstCall-AsiaNet - The LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that it has signed an agreement with China National Pharmaceutical Foreign Trade Corporation (Sinopharm Foreign Trade).
The corporation is a sales arm of China's largest pharmaceutical firm, China National Pharmaceutical Group (Sinopharm Group), for the distribution of LAM's IPM Wound Gel throughout China.
Dating back to 1950s, the Sinopharm Group has evolved from the former State Pharmaceutical Administration of China into the largest pharmaceutical distribution system today, with the most extensive market coverage in all regions of China.
The Sinopharm Group markets both Chinese and western pharmaceutical products, medical devices and pharmaceutical and chemical materials.
The Group's consolidated revenues for 2003 amounted to RMB 13.0 billion ($US1.63 billion).
Sinopharm Foreign Trade is the largest sales subsidiary within the Sinopharm Group of companies, in terms of import and export volume.